CXCL4/PF4 is a Predictive Biomarker of Cardiac Differentiation Potential of Human Induced Pluripotent Stem Cells

Overview

Journal Sci Rep

Specialty Science

Date 2019 Mar 16

PMID 30874579

Citations 11

Authors

Fumiya Ohashi

Shigeru Miyagawa

Satoshi Yasuda

Takumi Miura

Takuya Kuroda

Masayoshi Itoh

Hideya Kawaji

Emiko Ito

Shohei Yoshida

Atsuhiro Saito

Tadashi Sameshima

Jun Kawai

Yoshiki Sawa

Yoji Sato

Affiliations

Soon will be listed here.

Abstract

Selection of human induced pluripotent stem cell (hiPSC) lines with high cardiac differentiation potential is important for regenerative therapy and drug screening. We aimed to identify biomarkers for predicting cardiac differentiation potential of hiPSC lines by comparing the gene expression profiles of six undifferentiated hiPSC lines with different cardiac differentiation capabilities. We used three platforms of gene expression analysis, namely, cap analysis of gene expression (CAGE), mRNA array, and microRNA array to efficiently screen biomarkers related to cardiac differentiation of hiPSCs. Statistical analysis revealed candidate biomarker genes with significant correlation between the gene expression levels in the undifferentiated hiPSCs and their cardiac differentiation potential. Of the candidate genes, PF4 was validated as a biomarker expressed in undifferentiated hiPSCs with high potential for cardiac differentiation in 13 additional hiPSC lines. Our observations suggest that PF4 may be a useful biomarker for selecting hiPSC lines appropriate for the generation of cardiomyocytes.

Citing Articles

Transcriptome and epigenome dynamics of the clonal heterogeneity of human induced pluripotent stem cells for cardiac differentiation.

Yun J, So J, Jeong S, Jang J, Han S, Jeon J Cell Mol Life Sci. 2024; 82(1):2.

PMID: 39661125 PMC: 11635083. DOI: 10.1007/s00018-024-05493-9.

TMEM182 inhibits myocardial differentiation of human iPS cells by maintaining the activated state of Wnt/β-catenin signaling through an increase in ILK expression.

Morihara H, Yokoe S, Wakabayashi S, Takai S FASEB Bioadv. 2024; 6(11):565-579.

PMID: 39512841 PMC: 11539028. DOI: 10.1096/fba.2024-00086.

Considerations for the development of iPSC-derived cell therapies: a review of key challenges by the JSRM-ISCT iPSC Committee.

Madrid M, Lakshmipathy U, Zhang X, Bharti K, Wall D, Sato Y Cytotherapy. 2024; 26(11):1382-1399.

PMID: 38958627 PMC: 11471376. DOI: 10.1016/j.jcyt.2024.05.022.

Modeling mutation-specific arrhythmogenic phenotypes in isogenic human iPSC-derived cardiac tissues.

Maurissen T, Kawatou M, Lopez-Davila V, Minatoya K, Yamashita J, Woltjen K Sci Rep. 2024; 14(1):2586.

PMID: 38297132 PMC: 10831092. DOI: 10.1038/s41598-024-52871-1.

ROR2 expression predicts human induced pluripotent stem cell differentiation into neural stem/progenitor cells and GABAergic neurons.

Kuroda T, Yasuda S, Matsuyama S, Miura T, Sawada R, Matsuyama A Sci Rep. 2024; 14(1):690.

PMID: 38184695 PMC: 10771438. DOI: 10.1038/s41598-023-51082-4.

References

Fox J, Kausar F, Day A, Osborne M, Hussain K, Mueller A . CXCL4/Platelet Factor 4 is an agonist of CCR1 and drives human monocyte migration. Sci Rep. 2018; 8(1):9466. PMC: 6013489. DOI: 10.1038/s41598-018-27710-9. View

Ivey K, Muth A, Arnold J, King F, Yeh R, Fish J . MicroRNA regulation of cell lineages in mouse and human embryonic stem cells. Cell Stem Cell. 2008; 2(3):219-29. PMC: 2293325. DOI: 10.1016/j.stem.2008.01.016. View

Takeda M, Kanki Y, Masumoto H, Funakoshi S, Hatani T, Fukushima H . Identification of Cardiomyocyte-Fated Progenitors from Human-Induced Pluripotent Stem Cells Marked with CD82. Cell Rep. 2018; 22(2):546-556. DOI: 10.1016/j.celrep.2017.12.057. View

Nishizawa M, Chonabayashi K, Nomura M, Tanaka A, Nakamura M, Inagaki A . Epigenetic Variation between Human Induced Pluripotent Stem Cell Lines Is an Indicator of Differentiation Capacity. Cell Stem Cell. 2016; 19(3):341-54. DOI: 10.1016/j.stem.2016.06.019. View

Bon L, Affandi A, Broen J, Christmann R, Marijnissen R, Stawski L . Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med. 2013; 370(5):433-43. PMC: 4040466. DOI: 10.1056/NEJMoa1114576. View

Lee J, Lee J, Shapovalova Z, Fiebig-Comyn A, Mitchell R, Laronde S . Somatic transcriptome priming gates lineage-specific differentiation potential of human-induced pluripotent stem cell states. Nat Commun. 2014; 5:5605. DOI: 10.1038/ncomms6605. View

Kim H, Lee G, Ganat Y, Papapetrou E, Lipchina I, Socci N . miR-371-3 expression predicts neural differentiation propensity in human pluripotent stem cells. Cell Stem Cell. 2011; 8(6):695-706. DOI: 10.1016/j.stem.2011.04.002. View

Rosenblatt-Velin N, Lepore M, Cartoni C, Beermann F, Pedrazzini T . FGF-2 controls the differentiation of resident cardiac precursors into functional cardiomyocytes. J Clin Invest. 2005; 115(7):1724-33. PMC: 1143587. DOI: 10.1172/JCI23418. View

Sougawa N, Miyagawa S, Fukushima S, Kawamura A, Yokoyama J, Ito E . Immunologic targeting of CD30 eliminates tumourigenic human pluripotent stem cells, allowing safer clinical application of hiPSC-based cell therapy. Sci Rep. 2018; 8(1):3726. PMC: 5829260. DOI: 10.1038/s41598-018-21923-8. View

10.

Kurosawa H . Methods for inducing embryoid body formation: in vitro differentiation system of embryonic stem cells. J Biosci Bioeng. 2007; 103(5):389-98. DOI: 10.1263/jbb.103.389. View

11.

Lanner F, Rossant J . The role of FGF/Erk signaling in pluripotent cells. Development. 2010; 137(20):3351-60. DOI: 10.1242/dev.050146. View

12.

Sun N, Yazawa M, Liu J, Han L, Sanchez-Freire V, Abilez O . Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med. 2012; 4(130):130ra47. PMC: 3657516. DOI: 10.1126/scitranslmed.3003552. View

13.

Takeda M, Miyagawa S, Fukushima S, Saito A, Ito E, Harada A . Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells. Tissue Eng Part C Methods. 2017; 24(1):56-67. PMC: 5757089. DOI: 10.1089/ten.TEC.2017.0247. View

14.

Yoshida E, Terao Y, Hayashi N, Mogushi K, Arakawa A, Tanaka Y . Promoter-level transcriptome in primary lesions of endometrial cancer identified biomarkers associated with lymph node metastasis. Sci Rep. 2017; 7(1):14160. PMC: 5658375. DOI: 10.1038/s41598-017-14418-5. View

15.

Kawamura T, Miyagawa S, Fukushima S, Maeda A, Kashiyama N, Kawamura A . Cardiomyocytes Derived from MHC-Homozygous Induced Pluripotent Stem Cells Exhibit Reduced Allogeneic Immunogenicity in MHC-Matched Non-human Primates. Stem Cell Reports. 2016; 6(3):312-20. PMC: 4788782. DOI: 10.1016/j.stemcr.2016.01.012. View

16.

Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4):663-76. DOI: 10.1016/j.cell.2006.07.024. View

17.

Vandercappellen J, Van Damme J, Struyf S . The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. Cytokine Growth Factor Rev. 2010; 22(1):1-18. DOI: 10.1016/j.cytogfr.2010.10.011. View

18.

Kattman S, Witty A, Gagliardi M, Dubois N, Niapour M, Hotta A . Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell. 2011; 8(2):228-40. DOI: 10.1016/j.stem.2010.12.008. View

19.

Yasuda S, Hasegawa T, Hosono T, Satoh M, Watanabe K, Ono K . AW551984: a novel regulator of cardiomyogenesis in pluripotent embryonic cells. Biochem J. 2011; 437(2):345-55. DOI: 10.1042/BJ20110520. View

20.

Sugimoto M, Kondo M, Koga Y, Shiura H, Ikeda R, Hirose M . A simple and robust method for establishing homogeneous mouse epiblast stem cell lines by wnt inhibition. Stem Cell Reports. 2015; 4(4):744-57. PMC: 4400648. DOI: 10.1016/j.stemcr.2015.02.014. View